このエントリーをはてなブックマークに追加
ID 30795
JaLCDOI
FullText URL
Author
Matsuo, Keisuke
Kiura, Katsuyuki Kaken ID
Ueoka, Hiroshi
Shibayama, Takuo
Matsumura, Tadashi
Takigawa, Nagio
Hiraki, Shunkichi
Harada, Mine
Abstract

We have established an Adriamycin (ADM) -resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM100, which shows multifactorial mechanisms of resistance to ADM, such as overexpression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. In the present study, we confirmed that SBC-3/ADM 100 showed collateral sensitivity to methotrexate and TNP-351, a new antifolate, though this cell line showed a typical multidrug resistance (MDR) pattern. We also demonstrated a faster uptake and higher accumulation (1.3-fold) of TNP-351 in the SBC-3/ADM100 cells than those in the parent SBC-3 cells. These results explain one of the mechanisms for collateral sensitivity in the resistant cells. Furthermore, this cell line was found to have no cross-resistance to edatrexate and minimal cross-resistance to trimetrexate, 254-S (cisplatin analog), 5-fluorouracil and 4-hydroperoxyifosfamide. These drugs will have clinical importance in patients with SCLC who were previously treated with an ADM-containing regimen. Thus, antifolates, especially TNP-351 and edatrexate, can be expected to eradicate residual multidrug resistant SCLC cells selected by ADM.

Keywords
Adriamycin-resistant cell line
antifolates
small cell lung cancer
Amo Type
Article
Published Date
1997-06
Publication Title
Acta Medica Okayama
Volume
volume51
Issue
issue3
Publisher
Okayama University Medical School
Start Page
121
End Page
127
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
File Version
publisher
Refereed
True
PubMed ID
Web of Science KeyUT